| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA1614364 | Binding | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1). (Class of assay: confirmatory) | Homo sapiens | 11,958 | ALA1201862 | single protein format | PubChem BioAssays | |
| 2. | ALA3301363 | Physicochemical | ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5 | 4,197 | ALA3301361 | small-molecule physicochemical format | AstraZeneca Deposited Data | ||
| 3. | ALA3301365 | ADME | ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma at 37C for >5hrs. Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound. | Homo sapiens | 1,614 | ALA3301361 | cell-free format | AstraZeneca Deposited Data | |
| 4. | ALA4017550 | ADME | Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method | Homo sapiens | 621 | ALA4017441 | assay format | Scientific Literature | |
| 5. | ALA5303574 | ADME | The drug is tested on Bifidobacterium adolescentis strain: ATCC 15703 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Bifidobacterium adolescentis | 247 | ALA5303573 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | |
| 6. | ALA5303575 | ADME | The drug is tested on Bifidobacterium breve strain: DSM20213 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Bifidobacterium breve | 225 | ALA5303573 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | |
| 7. | ALA5303577 | ADME | The drug is tested on Bifidobacterium ruminantium strain: fecal isolate for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Bifidobacterium ruminantium | 208 | ALA5303573 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | |
| 8. | ALA5303578 | ADME | The drug is tested on Collinsella aerofaciens strain: ATCC25986 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Collinsella aerofaciens | 258 | ALA5303573 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | |
| 9. | ALA5303579 | ADME | The drug is tested on Collinsella intestinalis strain: DSM13280 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Collinsella intestinalis | 254 | ALA5303573 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | |
| 10. | ALA5303581 | ADME | The drug is tested on Alistipes indistinctus strain: DSM22520 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Alistipes indistinctus | 202 | ALA5303573 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | |
| 11. | ALA5303582 | ADME | The drug is tested on Bacteroides caccae strain: ATCC43185 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Bacteroides caccae | 239 | ALA5303573 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | |
| 12. | ALA5303583 | ADME | The drug is tested on Bacteroides cellulosilyticus strain: DSM14838 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Bacteroides cellulosilyticus | 196 | ALA5303573 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | |
| 13. | ALA5303584 | ADME | The drug is tested on Bacteroides coprophilus strain: DSM18228 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Bacteroides coprophilus | 227 | ALA5303573 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | |
| 14. | ALA5303585 | ADME | The drug is tested on Bacteroides dorei strain: DSM17855 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Phocaeicola dorei | 223 | ALA5303573 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | |
| 15. | ALA5303586 | ADME | The drug is tested on Bacteroides eggerthii strain: DSM20697 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Bacteroides eggerthii | 244 | ALA5303573 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | |
| 16. | ALA5303587 | ADME | The drug is tested on Bacteroides finegoldii strain: DSM17565 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Bacteroides finegoldii | 238 | ALA5303573 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | |
| 17. | ALA5303588 | ADME | The drug is tested on Bacteroides fragilis strain: NCTC 9343 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Bacteroides fragilis | 234 | ALA5303573 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | |
| 18. | ALA5303589 | ADME | The drug is tested on Bacteroides fragilis strain: 3397 (T10) for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Bacteroides fragilis | 229 | ALA5303573 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | |
| 19. | ALA5303590 | ADME | The drug is tested on Bacteroides fragilis strain: T(B)9 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Bacteroides fragilis | 217 | ALA5303573 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | |
| 20. | ALA5303591 | ADME | The drug is tested on Bacteroides fragilis strain: DS-208 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Bacteroides fragilis | 235 | ALA5303573 | assay format | Zimmerman Lab Biotransformation data Dec 2023 |
The page will load shortly, Thanks for your patience!